<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=780280282443813&amp;ev=PageView&amp;noscript=1">
search

    Aptevo Therapeutics Inc.

    verified_userVerify Profile
    Companies » Health Care » Health Care Equipment & Services » Biotechnology

    About Aptevo Therapeutics Inc.

    Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer and autoimmune diseases. Source

    At A Glance

    • CAPITAL RAISE STATUS
      Not Currently Raising
    • FILING TYPE
      Public
    • PLATFORM TYPE
      NASDAQ
    • RAISED AMOUNT
      $X,XXX,XXX
    • PRE-MONEY EVAULATION
      $X,XXX,XXX
    • SIC CODE
      2834
    • NIN CODE
      ####
    • LEADERSHIP
      Marvin L. White
    • FOUNDED
      2016
    • EMPLOYEES
      101-250
    • SECTOR
      Health Care Equipment & Services
    • SUBSECTOR
      Biotechnology

    Company Tags

    No articles found.

    Magnabid

    Magnabid

    Founded in 2015 and based in Los Angeles, California. Magnabid.com is a trusted me...

    Founded in 2015 and based in Los Angeles, Calif...

    Amount Raised:    $14,008.05
    Fundraising Status:    EC
    Filing Type:    CF
    Angle PLC

    Angle PLC

    ANGLE is a world leading liquid biopsy company with pioneering products in cancer ...

    ANGLE is a world leading liquid biopsy company ...

    Amount Raised:    $250,000
    Fundraising Status:    VT
    Filing Type:    PU
    Evoke Pharma, Inc.

    Evoke Pharma, Inc.

    Evoke Pharma, Inc. (NASDAQ: EVOK) is a specialty pharmaceutical company focused pr...

    Evoke Pharma, Inc. (NASDAQ: EVOK) is a specialt...

    Filing Type:    PU
    LogicBio Therapeutics, Inc.

    LogicBio Therapeutics, Inc.

    LogicBio is a Cambridge, MA-based genome editing company focused on delivering the...

    LogicBio is a Cambridge, MA-based genome editin...

    Filing Type:    PU
    Biogen Inc.

    Biogen Inc.

    At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers...

    At Biogen, our mission is clear: we are pioneer...

    Filing Type:    PU
    Guardant Health, Inc.

    Guardant Health, Inc.

    We are a leading precision oncology company focused on helping conquer cancer glob...

    We are a leading precision oncology company foc...

    Filing Type:    PU
    Replimune Group, Inc.

    Replimune Group, Inc.

    Cancer is one of the most difficult diseases to treat. It is constantly changing, ...

    Cancer is one of the most difficult diseases to...

    Filing Type:    PU
    OncoSec Medical Incorporated

    OncoSec Medical Incorporated

    OncoSec Medical Incorporated is a clinical-stage biotechnology company focused on ...

    OncoSec Medical Incorporated is a clinical-stag...

    Filing Type:    PU
    IMV Inc.

    IMV Inc.

    IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunot...

    IMV Inc. is a clinical stage biopharmaceutical ...

    Filing Type:    PU
    NGM Biopharmaceuticals, Inc.

    NGM Biopharmaceuticals, Inc.

    We are a clinical stage biopharmaceutical company focused on harnessing powerful b...

    We are a clinical stage biopharmaceutical compa...

    Filing Type:    PU
    Curis, Inc.

    Curis, Inc.

    Curis is a biotechnology company focused on the development and commercialization ...

    Curis is a biotechnology company focused on the...

    Filing Type:    PU
    Nektar Therapeutics

    Nektar Therapeutics

    Nektar Therapeutics is a research-based development stage biopharmaceutical compan...

    Nektar Therapeutics is a research-based develop...

    Filing Type:    PU
    ©2026 National Investor Network. All Rights Reserved.